Navigation Links
Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher

amage, coma and death.

If a diagnosis is made quickly enough, dialysis can help to cleanse the blood of excess nitrogen during an episode and prevent brain damage.

Traditional treatments included maintaining a very-low protein diet that is still high enough in calories to avoid metabolizing any of the body's protein-rich muscle. Liver transplantation is also an option for some patients.

This study investigated whether drugs that promote alternative pathways to dismantle and excrete nitrogen-containing waste can lower the dangerously high levels of blood ammonia, called hyperammonemia.

The 299 people in the study experienced 1,181 episodes of hyperammonemia during the study period. Those who received the drug therapy had an overall survival rate of 73 percent for newborns and 98 percent for older patients. In contrast, a recent European study of 217 patients who did not receive the therapy reported overall survival rates of only 16 percent for newborns and 72 percent for people with later onset of disease.

Urea cycle disorders can become apparent at many different stages in life. Newborns with a complete blockage in the cycle begin to show symptoms within hours after birth but are often misdiagnosed. Older children or adults with less-severe mutations can lead normal lives until sickness or a change in diet overtax the body and bring on a life-threatening episode.

Only a fraction of the many possible mutations are picked up by expanded newborn screening, and precious days are lost while test results are processed. The lethargy, vomiting and rapid breathing exhibited by affected newborns are often misinterpreted and mistreated as hospital-acquired infections. "Newborn screening is good at detecting some urea cycle disorders, but we can't diagnose all of them this way," said Enns. "By the time the results come back, these kids are already in the hospital and going into a coma. The sooner you identify them, the better the possib
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
2. Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients
3. Study Shows Metabolic Strategy of Stressed Cell
4. IMPAX Presents at Movement Disorder Societys 11th International Congress of Parkinsons Disease and Movement Disorders
5. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
6. Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’
7. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
Post Your Comments:
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating ... clinically meaningful extension of progression-fr...zumab to attack both the inside and,outside of the...ckade, -- Data demonstrating activity of TYKERB a...tiple lines of trastuzumab and chemotherapy, LOND...
(Date:5/16/2008)... - ANX-530 Demonstrates Statistically Significant ...fety Observations, - Abstract to be published in 2... Clinical Oncology, SAN DIEGO, ...uticals,Inc. (Amex: ANX ) announced today that, ... ANX-530 demonstrated a statistically significant ...
(Date:5/15/2008)... - First in human clinical data highlight safety ...h advanced solid tumors -, BRISBANE, Calif., May ...ly held biopharmaceutical company developing novel...rting its lead PARP inhibitor, BSI-201, will,be pr...ncology annual,meeting in Chicago., Findings will...
(Date:5/15/2008)... KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/...eader in advancing the science and treatment of,ch... today that data from,several clinical studies wit...L(R) (ribavirin, USP) combination therapy, as well... HCV protease inhibitor, will be presented at,the ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Family history of alcoholism affects response to drug used to treat heavy drinking 1563 1Family history of alcoholism affects response to drug used to treat heavy drinking 1563 2New study shows fish respond quickly to changes in mercury deposition 452 1New study shows fish respond quickly to changes in mercury deposition 452 2New study shows fish respond quickly to changes in mercury deposition 452 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 1 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 2 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 4IsoTis Integra Merger 678 1IsoTis Integra Merger 678 2IsoTis Integra Merger 678 3IsoTis Integra Merger 678 4IsoTis Integra Merger 678 5
...RN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X,an...e version of,the journal Blood demonstrated that i...tent cytotoxic responses against,patient-derived m...,enhanced anti-myeloma effects when used as a comb...ifically designed to inhibit all,relevant members ...
...NESS WIRE)--Mar 7, 2007 - Advanced Viral,Research ...cal,company, announced today that new information ... 2007 Proceedings of the American,Society of Clini...lication will be distributed to the nearly 25,000 ...ar,s meeting in Chicago on,June 1-5., Based on rec...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 3
(Date:5/16/2008)...hy Back Acquires Rival JoAnne,s Bed & Back; Merger... Company Owned Back Retail Chain, LORTON, Va., Ma...,company whose focus on home and workplace back we...ed all substantial assets of its rival,JoAnne,s B...division,claimed 2007 revenues of $40million. JoAn...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...rs could report side effects, but critics want age...ay 16 (HealthDay News) -- Direct-to-consumer drug ... number that would allow consumers to report adver...day. , The experts serve on a panel that advise...e numbers are already mandated by the FDA for prin...
(Date:5/16/2008)...long Campaign to Emphasize the Importance of Oral ...wswire/ -- National dental insurer United,Concordi...llaboration,between Oral Health America and the Br...rtance of oral health to overall health. Beginning...ted States for the first time,making it the large...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:United Concordia Dental Celebrates National Smile Month 2
...'s B.M. Birla Heart Research Centre Friday became ...ccreditation// in recognition of its high quality ...r Hospitals and Health Service Providers (NABH) ce...nt of our focus on quality", Suyash Borar, the hos...
...e of the biggest controversies in fetal surgery an...ternal-fetal medicine physicians// around the worl...ion syndrome (TTTS), one of the most common condit...eading cause of mortality in twins? The benchmark...
...ne Sherwood-Puzzello, a clinical assistant profess...of Applied Health Science//, has offered some tips...on sex with their teenage children. Teenage is th...of growing up. Love and romance form an integral p...
...rch aimed to study the significance of thyroid che...searchers are considering whether thyroid check up...if no symptoms of the disease are seen. Previous s...y under active or a hyperactive thyroid gland duri...
Other Medicine News:Health News:Timeliness, a Critical Factor in Treating TTTS 2Health News:Timeliness, a Critical Factor in Treating TTTS 3Health News:Pregnant? Check Your Thyroid Secretion! 2
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte
IDS Rapid ANA II System, a microbial identification system.
IDS Rapid SS/u, a microbial identification system.
IDS Rapid NF Plus, a microbial identification system.
Medicine Products: